Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
Esperion (NASDAQ: ESPR) announced that two analyses from the CLEAR Outcomes trial were accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, November 7-10, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Esperion (NASDAQ: ESPR) announced that two analyses from the CLEAR Outcomes trial were accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, November 7-10, 2025.
An oral presentation titled “Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial” is scheduled for November 9, 2025, 9:45–11:00 AM CST, presented by Carolina Pires Zingano, MD of Cleveland Clinic. A poster, “Effects of Bempedoic Acid on Venous Thromboembolism: a Post-Hoc Analysis of the CLEAR Outcomes trial”, will appear in the moderated digital poster session VM.MDP.07 on November 9, 2025, 11:50 AM–1:05 PM CST, presented by Bernardo Frison Spiazzi, MD of Cleveland Clinic.
Company leadership highlighted that CLEAR Outcomes continues to yield clinically relevant insights on statin intolerance and treatment options for patients with elevated LDL-C.
Details
News Market Reaction – ESPR
On Oct 27, the day this news came out, ESPR closed 7.01% above the previous close.
Data tracked by StockTitan Argus for the Oct 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, November 7-10, 2025.
Oral Presentation
Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial
November 9, 2025, 9:45 – 11:00 AM CST
Presenter: Carolina Pires Zingano, MD (Cleveland Clinic)
Poster Presentation
Effects of Bempedoic Acid on Venous Thromboembolism: a Post-Hoc Analysis of the CLEAR Outcomes trial
Moderated Digital Poster Session, VM.MDP.07 Top Clinical and Translational Abstracts in Vascular Medicine:
November 9, 2025, 11:50 AM – 1:05 PM CST
Presenter: Bernardo Frison Spiazzi, MD (Cleveland Clinic)
“The landmark CLEAR Outcomes trial continues to provide clinically meaningful insights that highlight the challenges of statin intolerance and reinforce the importance of expanding treatment options for patients at risk of cardiovascular events due to elevated LDL-C,” said Sheldon Koenig, president and CEO of Esperion.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.